Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 192

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

Open access
Kowdley, Kris V., Vuppalanchi, Raj, Levy, Cynthia, Floreani, Annarosa, Andreone, Pietro, LaRusso, Nicholas F., Shrestha, Roshan, Trotter, James, Goldberg, David, Rushbrook, Simon, Hirschfield, Gideon M., Schiano, Thomas, Jin, Yuying, Pencek, Richard, MacConell, Leigh, Shapiro, David, Bowlus, Christopher L.·2020·Journal of Hepatology

Abstract

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease with no currently approved therapies. Obeticholic acid (OCA) is a potent farnesoid X receptor (FXR) agonist approved for the treatment of primary biliary cholangitis. We investigated the efficacy and safety of OCA in patients with PSC. METHODS: AESOP was a phase II, randomized, double-blind, placebo-controlled, dose-finding study. Eligible patients were 18 to 75 years of age with a diagnosis of PSC and serum alkaline phosphatase (ALP) ≥2× the upper limit of normal (ULN) and total bilirubin <2.5× ULN. Patients were randomized 1:1:1 to receive placebo, OCA 1.5-3.0 mg, or OCA 5-10 mg once daily for a 24-week, double-blind phase followed by a 2-year, long-term safety extension (LTSE). Primary endpoints were change in ALP from baseline to week 24, and safety. RESULTS: The intent-to-treat population comprised 76 patients randomized to placebo (n = 25), OCA 1.5-3.0 mg (n = 25), and OCA 5-10 mg (n = 26). At week 24, serum ALP was significantly reduced with OCA 5-10 mg vs. placebo (least-square [LS] mean difference = -83.4 [SE = 40.3] U/L; 95% CI -164.28 to -2.57; p = 0.043). Serum ALP was not significantly reduced with OCA 1.5-3.0 mg vs. placebo at week 24 (LS mean [SE] difference = -78.29 [41.81] U/L; 95% CI -162.08 to 5.50; p = 0.067). Total bilirubin remained comparable to baseline in all groups. The most common treatment-emergent adverse event was dose-related pruritus (placebo 46%; OCA 1.5-3.0 mg 60%; OCA 5-10 mg 67%). Reductions in ALP were maintained during the LTSE, and no new safety signals emerged. CONCLUSIONS: Treatment with OCA 5-10 mg reduced serum ALP in patients with PSC. Mild to moderate dose-related pruritus was the most common adverse event. REGISTRATION: ClinicalTrials.gov: NCT02177136; EudraCT: 2014-002205-38. LAY SUMMARY: Primary sclerosing cholangitis (PSC) is a long-term disease that damages the bile ducts in the liver over time. In the AESOP clinical study in patients with PSC, obeticholic acid reduced serum alkaline phosphatase (a potential marker of disease severity) during an initial 24-week treatment period. The result was sustained during the 2-year, long-term extension of the study. The most common side effect of obeticholic acid in the study was itchy skin, which is consistent with earlier clinical studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2020.02.033

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 192

Metadata

Authors
Kowdley, K. V., Vuppalanchi, R., Levy, C., Floreani, A., Andreone, P., LaRusso, N. F., Shrestha, R., Trotter, J., Goldberg, D., Rushbrook, S., Hirschfield, G. M., Schiano, T., Jin, Y., Pencek, R., MacConell, L., Shapiro, D., & Bowlus, C. L.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2020-07
Volume
73
Issue
1
Pages
94-101
ISSN
0168-8278 (ISSN-L)
OpenAlex
W3011514631
Cited by
192
References
8
FWCI
14.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. https://app.cochat.ai/papers/10.1016/j.jhep.2020.02.033
The paper
Kowdley, K. V., Vuppalanchi, R., Levy, C., Floreani, A., Andreone, P., LaRusso, N. F., Shrestha, R., Trotter, J., Goldberg, D., Rushbrook, S., Hirschfield, G. M., Schiano, T., Jin, Y., Pencek, R., MacConell, L., Shapiro, D., & Bowlus, C. L. (2020). A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.02.033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.